Successful treatment of refractory low grade duodenal lymphoma with rituximab, an anti-CD20 monoclonal antibody

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 4, 2003, Pages 408-410

  Ahmed, Shazia ^b   Singh, Aman ^b   Krauss, John ^b   Wentz, Tracey ^b   Gunaratnam, Naresh T ^a  

^a ST JOSEPH MERCY HOSPITAL   (United States)

^b NONE

Author keywords

Intestinal lymphoma; Monoclonal antibody

Indexed keywords

CD20 ANTIGEN; CYCLOPHOSPHAMIDE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; CANCER GRADING; CANCER REGRESSION; CANCER SURVIVAL; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DUODENUM CANCER; FEMALE; HUMAN; HUMAN TISSUE; LYMPHOMA; PROGNOSIS; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DUODENAL NEOPLASMS; FEMALE; HUMANS; LYMPHOMA, LOW-GRADE; TREATMENT FAILURE;

EID: 0042062436     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200308000-00021     Document Type: Article

References (12)

1. Shibata Y. Primary malignant lymphoma of the duodenum: Report of a case. Hepatogastroenterology 1998;45:2171-4.
2. Yoshino T. Increased incidence of follicular lymphoma in the duodenum. Am J Surg Pathol 2000;24:688-93.
3. Kosits C, Callaghan M. Rituximab. A new monoclonal antibody therapy for non-Hodgkin's lymphoma. Oncol Nurs Forum 2000; 27:51-9.
4. Cunningham J, Aleali R. Advances in surgical technique. Ann Surg 1997;225:300-6.
5. Gopal A, Press O. Clinical applications of anti-CD20 antibodies. J Lab Clin Med 1999;134:445-50.
6. Kawai T. Lymphoma arising in mucosa associated lymphoid tissue of the duodenal bulb. J Gastroenterol 1998;33:97-101.
7. Hainsworth J, Burris HA 3rd, Morrissey LH, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkins lymphoma. Blood 2000;95:3052-6.
8. Maloney D, Grillo-Lopez A, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkins lymphoma. Blood 1997;90:2188-95.
9. Davis T, White C, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999;17:1851-7.
10. Foran J, Gupta R, et al. A UK Multicenter phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol 2000;109:81-9.
11. McLaughlin P, Hagemeister F, et al. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol 1999;26:70-87.
12. Scott S. Rituximab. A new therapeutic monoclonal antibody for non-Hodgkins lymphoma. Cancer Practice 1998;6:195-7.